DMAC
DiaMedica Therapeutics Inc.
Biotechnology · Healthcare · United States
9.25
close · 2026-10-30
value
88
cheaper than peers88
quality
60
stronger fundamentals60
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -5.6% | 85 |
| cash flow yield, 3 years ago | -2.3% | 83 |
| earnings yield, 2 years ago | -6.5% | 82 |
| earnings yield, latest year | -7.6% | 80 |
| earnings yield, 1 year ago | -6.5% | 80 |
| cash flow yield, latest year | -5.8% | 79 |
| cash flow yield, 1 year ago | -4.4% | 76 |
| cash flow yield, 2 years ago | -3.8% | 74 |
| price to book | 13.01× | 11 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.4% | 84 |
| operating margin | 0.0% | 50 |
| return on equity | -86.5% | 33 |
3 of 4 measures available
Facts
| market cap | $499M |
| free cash flow | -$18.0M |
| employees | 35 |
| first trade | 2012-08-03 |
| next earnings | 2026-08-10 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.70 | -0.60 | -0.60 | -0.52 |
| free cash flow | -$29.1M | -$22.1M | -$18.8M | -$11.6M |
| net income | -$32.8M | -$24.4M | -$19.4M | -$13.7M |
| revenue | $0 | $0 | $0 | $0 |